Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer
2018 · EBioMedicine · 215 citations
https://doi.org/10.1016/j.ebiom.2018.11.004
P
Pınar Kanlikilicer
Sanofi (France)(FR)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
67
Papers
1.4K
Citations
14
h-index
14
i10-index
Pınar Kanlikilicer is an academic researcher from Sanofi (France). The author has contributed to research in topics: MicroRNA in disease regulation & Circular RNAs in diseases & Extracellular vesicles in disease. The author has an h-index of 14, co-authored 57 publications.
Papers by this author
worksTherapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models
2017 · Molecular Therapy — Nucleic Acids · 78 citations
https://doi.org/10.1016/j.omtn.2017.06.023
ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer
2021 · Molecular Therapy — Nucleic Acids · 48 citations
https://doi.org/10.1016/j.omtn.2021.01.016
The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers
2018 · Molecular Therapy — Nucleic Acids · 34 citations
https://doi.org/10.1016/j.omtn.2018.11.019
Corrigendum to ‘Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer’ [EBioMedicine 38 (2018) 100–112]
2020 · EBioMedicine · 7 citations
https://doi.org/10.1016/j.ebiom.2020.102630
40O Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
2025 · ESMO Open · 2 citations
https://doi.org/10.1016/j.esmoop.2025.104199
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat